Lung

(108-25) A Phase 1 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

(110-25) Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants with Metastatic Solid Tumors

(120-25) A Phase 1/2, Open-Label, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-Mutant-Selective PI3Kα Inhibitor, as Monotherapy and in Combination with Other Anticancer Therapies in Participants with Advanced Solid Tumors

(121-25) A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II-IIIB (N2) Non-small Cell Lung Cancer

(141-25) A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer

(142-25) A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Confirmation Study of BHV-1530 in Adult Participants with Advanced or Metastatic Solid Tumors

(146-22) LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

(146-25) A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

(148-24) A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Subjects with Carcinoid Syndrome and Well-Differentiated Neuroendocrine Tumor

(157-24) A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer

(167-25) A Phase Ia/Ib multicenter, open-label trial to evaluate safety, tolerability, and efficacy and dosimetry of LY4337713, a FAP-targeted radioligand therapy, in adults with FAP-positive advanced solid tumors

(169-24)The Effect of Pre operative Meditation Coaching on Adoption of Meditation Practice, Peri Operative pain, Distress and Medication Use (169-25) A Phase 1 Dose-Escalation Study of SLV-324 in Subjects with Metastatic Solid Tumors

(177-24) A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants with Advanced-Stage Tumors

(179-24) A Phase 1 Dose-Escalation Study of SLV-154 in Subjects with Metastatic Solid Tumors

(186-24) A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors

(188-24) Phase 1 study of ACR-2316 in subjects with advanced solid tumors

(232-24) A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

(235-24) Phase 1b expansion of STK-012, a first-in-class IL-2R α/β partial agonist cytokine, in combination with standard of care treatment (pembrolizumab + pemetrexed + carboplatin) in first line non-squamous PD-L1 negative NSCLC

(237-24) Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors

(239-24) A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

(240-23) SLC-391-102 (SKYLITE Study), A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

(240-24) Pilot study of characterization of hereditary cancer-associated germline variants with long-read sequencing (LRS)

(246-23) An open-label, multicenter, first-in-human Phase 1a/1b study to evaluate safety and tolerability of QXL138AM in participants with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma

(248-24) A Phase 1b, 2-part, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients with Previously Treated Locally Advanced or Metastatic Solid Tumors